Enhertu access in Bangladesh: the DGDA named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Bangladesh access Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-positive and HER2-low metastatic breast cancer in adults, HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, HER2-mutant unresectable or metastatic non-small cell lung cancer, and HER2-positive (IHC 3+) unresectable or metastatic solid tumors after prior systemic therapy through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

Why Bangladeshi patients need Enhertu through the named-patient pathway

The People's Republic of Bangladesh operates a structured pharmaceutical regulatory environment. Enhertu (fam-trastuzumab deruxtecan-nxki) is regulated through DGDA (Directorate General of Drug Administration) channels, and a Bangladeshi family asking for Enhertu is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag. Enhertu's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Bangladesh or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the DGDA named-patient pathway is the mechanism that connects a Bangladeshi-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Enhertu is a HER2-directed antibody-drug conjugate combining a humanised anti-HER2 IgG1 monoclonal antibody with a topoisomerase I inhibitor payload (deruxtecan) via a cleavable tetrapeptide linker, administered as an IV infusion every 3 weeks, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.

Current regulatory status of Enhertu in Bangladesh

Enhertu (trastuzumab deruxtecan; Daiichi Sankyo / AstraZeneca) is a HER2-directed antibody-drug conjugate with a topoisomerase-I-inhibitor payload (deruxtecan), administered as a 30 to 90 minute IV infusion every three weeks. As of 2026-05-31, the DGDA Registered Imported Drugs list contains no public record of a local marketing authorisation for trastuzumab deruxtecan; the originator trastuzumab and several biosimilar trastuzumab products are locally registered, but the antibody-drug-conjugate is not publicly documented as a Bangladesh-registered finished product.

Cross-border access is therefore authorised case-by-case by the Director General, DGDA under Section 13 of the Drugs (Control) Ordinance 1982. The most common route is the institutional channel through a tertiary oncology hospital pharmacy. The file specifies HER2 testing status (IHC 3+, IHC 2+ ISH+, or HER2-low IHC 1+ / IHC 2+ ISH-negative), tumour primary, and prior-therapy history matching the FDA label.

The interstitial-lung-disease pharmacovigilance signal in the FDA label is material to the import file because DGDA's case-by-case review for high-toxicity oncology biologics often includes an explicit ILD-monitoring plan. Tertiary hospital pharmacies routinely add baseline and serial CT-thorax surveillance, pulse-oximetry follow-up, and ILD pharmacovigilance reporting to the file.

Last DGDA bulletin observed touching imported biologic regulation: 2025-01-14 Guideline for Quality Assurance of Locally Sourced Medical Products. Last verified by ARCH-74: 2026-05-31.

Named tertiary centres in Bangladesh where Enhertu is dispensed

Trastuzumab deruxtecan is administered in an oncology infusion centre with HER2-testing capability and access to interstitial-lung-disease monitoring. Bangladeshi referral centres equipped for this profile:

• National Institute of Cancer Research and Hospital (NICRH), Mohakhali, Dhaka - Medical Oncology, Gynaecological Oncology, and the breast-cancer multidisciplinary clinic; the largest public oncology infusion volume in the country.
• Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka - Medical Oncology, Gynaecological Oncology, and the breast and gastric clinics; HER2-testing laboratory on site.
• Square Hospitals Limited, Dhaka - private multi-specialty tertiary; oncology infusion centre with thoracic imaging and pulmonology pathway for ILD monitoring.
• Evercare Hospital Dhaka, Dhaka - private multi-specialty tertiary; medical oncology and breast-care unit.
• Ahsania Mission Cancer & General Hospital, Mirpur, Dhaka - charitable tertiary oncology hospital handling subsidised infusion cases.

HER2-testing reagent supply and turnaround time at NICRH and BSMMU is documented in their cancer-registry annual reports; private tertiaries typically run HER2 IHC and ISH in-house with same-week turnaround.

Local pricing reference for Enhertu in Bangladesh

US WAC reference for Enhertu (trastuzumab deruxtecan, 100 mg vial) is in the order of USD 2,750 to USD 3,150 per vial at the standard FDA-labelled regimen; per-cycle drug cost for a body-surface-area dosed adult at 5.4 mg/kg is in the order of USD 12,000 to USD 14,000 per dose for breast and gastric indications. The dosing regimen is the source of variance in patient-level cost. Source: Enhertu FDA Prescribing Information.

No public BDT reference price for trastuzumab deruxtecan has been observed on DGDA, NICRH, BSMMU, or major-importer published lists as of 2026-05-31. Importers customarily quote BDT at the spot USD/BDT rate published by Bangladesh Bank on the day of the proforma invoice plus permit, cold-chain logistics, and infusion-service overhead. We issue an itemised quotation at intake with the day-of-quote conversion shown.

Price snapshot date: 2026-05-31. Infusion-service charges (cycle-day infusion-chair time, prep-room pharmacy compounding, anti-emetic and pre-medication line-item) are billed by the dispensing hospital separately and are not part of the import line.

Country-specific access barriers for Enhertu in Bangladesh

The principal procedural barrier for trastuzumab deruxtecan in Bangladesh is the combination of cold-chain logistics (2 to 8 degree Celsius storage end-to-end) and the every-three-weeks chronic dosing schedule. Each cycle requires a fresh DGDA permission letter on the standard model; tertiary hospital pharmacies that have processed multiple cycles for a given patient often request a multi-cycle composite permission to reduce per-cycle paperwork, but this is at DGDA discretion and is not gazetted.

Public-sector funding posture for HER2-directed antibody-drug conjugates is constrained. The Ministry of Health and Family Welfare procurement budget covers single-agent trastuzumab biosimilar for some indications at NICRH and BSMMU; trastuzumab deruxtecan is not on the locally-procured list and is not funded under the standard MOHFW oncology programme as of 2026-05-31. The Honourable Prime Minister's Welfare Fund operates a case-by-case grant mechanism for high-cost medicines; applications are evaluated individually and grant timing is not predictable.

Private-insurance coverage of trastuzumab deruxtecan is policy-specific. Group-corporate plans through Pragati Life, Delta Life, MetLife Bangladesh, Green Delta, and Pioneer Insurance may cover a percentage subject to annual maximums; the per-cycle cost typically exhausts a standard annual maximum within the first two to four cycles. Out-of-pocket self-pay supplemented by family remittances and charitable channels (Ahsania Mission) is the dominant funding pattern. Daiichi Sankyo and AstraZeneca operate regional patient-access programmes; Bangladeshi application access varies by indication and by current programme parameters.

The customs and cold-chain handling for IV infusion biologics is established at Dhaka airport; Chattogram airport also handles refrigerated pharmaceutical clearance. Smaller regional dispensing centres typically do not have validated cold-chain receiving infrastructure and the import-file destination is almost always a Dhaka-based or Chattogram-based tertiary hospital pharmacy.

Recent local regulatory news touching Enhertu or its drug class in Bangladesh

No DGDA bulletin specifically naming trastuzumab deruxtecan or the HER2-ADC class has been observed in the last twelve months on the DGDA all-categories notices page as of 2026-05-31. Adjacent regulatory context relevant to the import workflow:

• 2025-01-14 - DGDA Guideline for Quality Assurance of Locally Sourced Medical Products tightens lot-by-lot QA expectations applied to imported biologic finished products. Source: DGDA Guideline PDF.
• The Bangladesh medicine-regulation reform Bill (planned to replace the 1982 Ordinance) is in active consultation and may restructure the case-by-case import-permission mechanism that currently underpins access to HER2-ADC therapy. Source: Dhaka Tribune coverage.

What your physician needs to provide

For a Bangladeshi-licensed specialist prescribing Enhertu through the DGDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for HER2-positive and HER2-low metastatic breast cancer in adults, HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, HER2-mutant unresectable or metastatic non-small cell lung cancer, and HER2-positive (IHC 3+) unresectable or metastatic solid tumors after prior systemic therapy, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Enhertu is the appropriate next step given a HER2-directed antibody-drug conjugate combining a humanised anti-HER2 IgG1 monoclonal antibody with a topoisomerase I inhibitor payload (deruxtecan) via a cleavable tetrapeptide linker, administered as an IV infusion every 3 weeks.

The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Enhertu (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Bangladeshi license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.

Common questions about Enhertu in Bangladesh

Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Enhertu is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DGDA? The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.

Can I receive Enhertu at home? The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Where Reserve Meds fits in Enhertu cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Enhertu specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Enhertu case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.

Next step

If your Bangladeshi physician has prescribed Enhertu and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Reserved for you.

---

Related

• Enhertu drug overview
• Bangladesh country page
• Named-patient pathway overview